GlassScriptPhysician profile
Ratika Gupta
NPI 1154611804
$10,703.01
in general payments reported to CMS, 2019-2025
28 companies · $4,623 in 2025
The $4,623 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $287 · 2021: $922 · 2022: $1,292 · 2023: $1,559 · 2024: $1,484 · 2025: $4,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,632 · Travel and Lodging: $1,034 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $833 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,632.28 |
| Travel and Lodging | $1,033.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $833.33 |
| Education | $167.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $2,371.08 | 2025 | Neffy |
| Genzyme Corporation | $1,570.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $983.12 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $918.76 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $904.38 | 2020-2025 | Dupixent |
| Alk-Abello, INC | $687.44 | 2020-2023 | Grastek, Ragwitek, Odactra |
| Inspire Medical Systems, INC. | $635.64 | 2023-2025 | Inspire |
| Optinose US, INC. | $391.16 | 2020-2025 | |
| Aerin Medical INC. | $307.37 | 2024-2025 | |
| Genentech USA, INC. | $200.94 | 2023-2025 | Xolair |
| Kaleo, INC. | $193.37 | 2021-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $158.98 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.34 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Pfizer INC. | $148.01 | 2019-2021 | |
| Organon LLC | $147.17 | 2025 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $141.93 | 2022-2025 | Opzelura |
| Csl Behring | $129.99 | 2023-2025 | Hizentra |
| Amgen INC. | $127.95 | 2023-2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $124.79 | 2021 | |
| Acclarent, INC | $84.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $81.93 | 2025 | |
| Hikma Pharmaceuticals USA | $69.34 | 2022-2024 | Ryaltris |
| Lilly USA, LLC | $60.43 | 2025 | Ebglyss, Zepbound, Mounjaro |
| Biocryst US Sales Co., LLC | $29.28 | 2025 | Orladeyo |
| Horizon Therapeutics Plc | $22.52 | 2022 | |
| Merck Sharp & Dohme LLC | $21.58 | 2021 | |
| Precigen, INC. | $18.00 | 2025 | |
| Phadia US INC. | $16.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratika Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.